Table 5.
In vitro susceptibility of isolates of multidrug-resistant P. aeruginosa collected in six Latin American countriesa divided into two 3-year time periods 2015‒2017 and 2018‒2020.
| Collection years (n) | Compound | Range | MIC50 | MIC90 | CLSI Interpretationb |
||
|---|---|---|---|---|---|---|---|
| (µg/mL) | %S | %I | %R | ||||
| 2015‒2017 (527) | Amikacin | 0.5 – > 32 | > 32 | > 32 | 43.5 | 6.3 | 50.3 |
| Aztreonam | 0.25 – > 128 | 64 | > 128 | 7.6 | 13.7 | 78.7 | |
| Cefepime | 4 – > 16 | > 16 | > 16 | 11.8 | 24.7 | 63.6 | |
| Ceftazidime | 0.25 – > 128 | 64 | > 128 | 15.2 | 6.3 | 78.6 | |
| Ceftazidime-avibactam | 0.25 – >128 | 8 | 64 | 53.9 | 0.0 | 46.1 | |
| Colistin | 0.12 – 8 | 1 | 2 | NA | 98.7 | 1.3 | |
| Imipenem | 0.25 – >8 | >8 | >8 | 12.7 | 1.3 | 86.0 | |
| Levofloxacin | 0.25 – > 8 | > 8 | > 8 | 8.3 | 4.0 | 87.7 | |
| Meropenem | 0.12 – > 8 | > 8 | > 8 | 8.2 | 4.9 | 86.9 | |
| Piperacillin Tazobactam | 4 – > 128 | > 128 | > 128 | 9.5 | 26.0 | 64.5 | |
| 2018‒2020 (633) | Amikacin | ≤ 0.25 – > 64 | 64 | > 64 | 34.1 | 7.0 | 58.9 |
| Aztreonam | 0.25 – > 128 | 32 | > 128 | 11.5 | 15.6 | 72.8 | |
| Cefepime | 4 – > 32 | 32 | > 32 | 6.0 | 23.4 | 70.6 | |
| Ceftazidime | 1 – > 128 | 64 | > 128 | 10.6 | 7.6 | 81.8 | |
| Ceftazidime-avibactam | 0.5 – > 128 | 16 | > 64 | 45.3 | 0.0 | 54.7 | |
| Colistin | ≤ 0.12 – > 8 | 1 | 2 | NA | 99.7 | 0.3 | |
| Imipenem | 1 – > 8 | > 8 | > 8 | 12.0 | 4.4 | 83.6 | |
| Levofloxacin | ≤ 0.25 – > 8 | > 8 | > 8 | 8.5 | 3.5 | 88.0 | |
| Meropenem | 0.12 – > 16 | > 16 | > 16 | 9.0 | 6.0 | 85.0 | |
| Piperacillin Tazobactam | ≤ 0.12 – > 64 | >64 | >64 | 4.9 | 30.6 | 64.5 | |
a
Countries included Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela.
b
S, susceptible; I, intermediate; R, resistant.